Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers
Lists
Only you see this
Abstract
Combination of gene expression-based classification and established prognostic markers improves risk estimation of patients with low-risk/intermediate-risk neuroblastoma. We propose to implement our revised treatment stratification system in a prospective clinical trial.
BibTeX
@inproceedings{oberthuer2014revised,
author = {André Oberthuer and Dilafruz Juraeva and Barbara Hero and Ruth Volland and Carolina Sterz and René Schmidt and Andreas Faldum and Yvonne Kahlert and Anne Engesser and Shahab Asgharzadeh and Robert C. Seeger and Miki Ohira and Akira Nakagawara and Paola Scaruffi and Gian Paolo Tonini and Isabelle Janoueix‐Lerosey and Olivier Delattre and Gudrun Schleiermacher and Jo Vandesompele and Frank Speleman and Rosa Noguera and Marta Piqueras and Jean Bénard and Alexander Valent and Smadar Avigad and Isaac Yaniv and Richard G. Grundy and Monika Ortmann and Chunxuan Shao and Manfred Schwab and Roland Eils and Thorsten Simon and Jessica Theißen and Frank Berthold and Frank Westermann and Benedikt Brors and Matthias Fischer},
title = {{Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers}},
booktitle = {Clinical},
year = {2014},
doi = {10.1158/1078-0432.ccr-14-0817},
}Loading related content...